Evidence map›Paper›PMID 31980412›Full record

ReviewJournal of geriatric oncology2020

Genetic cancer predisposition syndromes among older adults.

Yanin Chavarri-Guerra, Thomas P Slavin, Ossian Longoria-Lozano, Jeffrey N Weitzel

Open access · greenAbstract readReview
In one paragraph

Review in Journal of geriatric oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Genetic Predisposition to Sarcoma: What Should Clinicians Know?Current treatment options in oncology · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Yanin Chavarri-GuerraDepartment of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Thomas P SlavinDepartment of Medical Oncology, Division of Clinical Cancer Genomics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Ossian Longoria-LozanoDepartment of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Jeffrey N WeitzelDepartment of Medical Oncology, Division of Clinical Cancer Genomics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: jweitzel@coh.org.
City of Hope · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MX

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Clinical Cancer Genetics Community Network: A Sustainable Research PartnershipRC4CA153828 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WEITZEL, JEFFREY N · 2010 to 2010
$1.0M
Mentored Clinical Scientist Research Career Development Award (Parent K08)K08CA234394 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SLAVIN, THOMAS PAUL · 2018 to 2019
$498k
NCI NIH HHS K08 CA234394NCI NIH HHS P30 CA033572NCI NIH HHS RC4 CA153828
6 · The paper itself

Abstract

Earlier age at onset is one characteristic of hereditary cancer syndromes, so most studies of genetic testing have focused on young patients with cancer. However, recent studies of multigene panel tests in unselected cancer populations have detected a considerable proportion of older patients with germline pathogenic variants (PVs) in cancer susceptibility genes. As the number of older patients with cancer continues to rise, clinicians should be aware of genetic/genomic cancer risk assessment (GCRA) criteria in both young and older adults. Identifying individuals with a germline PV in a cancer susceptibility gene may be important for precision therapy of current cancers and screening and prevention of new primary cancers, as well as cascade testing to identify high cancer risks for family members. Typically, hereditary predisposition germline genetic testing has been recommended for patients with early onset cancers and/or a family history of cancer. However, more recently international guidelines recommend testing for potential therapeutic intervention regardless of age for some tumors frequently seen in older patients, such as epithelial ovarian, pancreatic, and metastatic prostate and breast cancers. GCRA in older patients may present challenges including: clonal hematopoiesis (CH) confounding test interpretation, ethical aspects (autonomy, nonmaleficence, beneficence), patient health status, comorbidities, as well as lack of insurance coverage. These factors should be considered during genetic counseling and when considering cancer screening and risk reduction procedures. This manuscript reviews available data on common hereditary cancer syndromes in older patients and provides tools to help providers perform GCRA in this population.

Indexed as

Breast NeoplasmsNeoplastic Syndromes, HereditaryAgedGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansMaleGermline pathogenic variantsHereditary cancerOlder patients

Identifiers

PMID31980412
PMCPMC7937543
OpenAlexW3002562714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.